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Regenerative medicineThe spectrum of ischaemic cardiomyopathy, encompassing acute myocardial infarction to congestive heart
failure is a signiﬁcant clinical issue in the modern era. This group of diseases is an enormous source of morbidity
and mortality and underlies signiﬁcant healthcare costs worldwide. Cardiac regenerative therapy, whereby pro-
regenerative cells, drugs or growth factors are administered to damaged and ischaemic myocardium has demon-
strated signiﬁcant potential, especially preclinically. While some of these strategies have demonstrated a measure
of success in clinical trials, tangible clinical translation has been slow. To date, the majority of clinical studies and a
signiﬁcant number of preclinical studies have utilised relatively simple delivery methods for regenerative thera-
peutics, such as simple systemic administration or local injection in saline carrier vehicles. Here, we review cardiac
regenerative strategies with a particular focus on advanced delivery concepts as a potential means to enhance
treatment efﬁcacy and tolerability and ultimately, clinical translation. These include (i) delivery of therapeutic
agents in biomaterial carriers, (ii) nanoparticulate encapsulation, (iii) multimodal therapeutic strategies and (iv)
localised, minimally invasive delivery via percutaneous transcatheter systems.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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This review encompasses drug and cell delivery for cardiac regener-
ation. This treatment can be cardioprotective; to protect heart muscle
tissue after an acute myocardial infarction (MI), or cardiorestorative;
to regenerate tissue in patients with chronic ischaemic heart failure.
Acute myocardial infarction occurs upon occlusion of one of the coro-
nary vessels, most commonly due to atherosclerotic plaque, resulting
in an ischaemic region of myocardium which, even if reperfused, can
produce lasting tissue damage with associated symptoms. Initially, MI
produces an inﬂammatory response and extensive ischaemic death of
cardiomyocytes within the affected area, resulting in a partial loss of
ventricular function. Over time, especially if the affected area is expan-
sive and transmural, complex alterations occur in the myocardium, a
phenomenon known as ventricular remodelling [1]. These adaptations
are an attempt to compensate for ventricular malfunction. However,
the heart possesses only a limited regenerative capacity. Remodelling
encompasses the creation of collagenous, non-contractile scar tissue,
thinning of the myocardial wall and progressive enlargement andFig. 1. Clinical trials in cell therapy: This ﬁgure shows the range and progression of cardiac cell
trend of moving from unselected cell populations and different cell types towards cardiopoietidilation of the ventricle. This ultimately contributes to a decrease in ven-
tricular contractile function and output. This can progress to congestive
heart failure (CHF), where the heart is unable to pump enough blood to
meet the metabolic demands of the body [2–4].
MI represents an enormous source of morbidity and mortality on a
global scale. Coronary artery diseases such as MI and CHF are the main
cause of death in developed countries, and pose a substantial healthcare
burden [3]. According to the European Society of Cardiology one in six
men andone in sevenwomen in Europewill die frommyocardial infarc-
tion [5]. The American Heart Association reports that 635,000
Americans have a new myocardial infarction each year and that the
number of deaths attributable to heart failure in the US in 2009 was
275,000 [6]. Current therapies for the treatment of MI and CHF include
pharmacological intervention, surgical procedures such as ventricular
resection, coronary artery bypass ormechanical aids such as left ventric-
ular assist devices. Such approaches serve to restore function or limit
disease progression to some degree, but are not always effective long-
term [7]. Reperfusion of the culprit artery (with coronary angioplasty
and/or stent placement) can have a profound effect on limiting infarcttherapy trials, with cell type underneath (graphically represented above) and depicts the
c and cardiac stem cells.
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ventricular remodelling with the objective of improving ventricular
function and clinical outcomes. However, myocardial necrosis begins
rapidly following coronary occlusion, usually before reperfusion can
be accomplished [9]. Post-infarction remodelling and the progression
to heart failure therefore remain a challenge in the treatment of cardio-
vascular disease. The most effective treatment for end-stage CHF is
heart transplantation, which is limited by the availability of heart
donors and also requires a highly invasive and complex surgical proce-
dure [2,7].
This review covers cell and drug delivery, and additional cell-free
approaches that share a common goal of enabling cardiac regeneration,
and attenuation or prevention of negative compensatory remodelling
(limiting infarct size, reducing or preventing infarct expansion and
reducing ventricular wall stress). These approaches have shown prom-
ise in addressing shortcomings in conventional cardioprotective and
cardiorestorative treatments for MI and CHF, respectively. However,
clinical translation of regenerative therapeutics has been slow to date.
Here, we suggest a perspective on how advanced delivery strategies
could be synergistically engaged in the facilitation of cardiac regenera-
tion, for enhanced efﬁcacy and treatment tolerability, with greater
potential for clinical translation.
2. Cell therapy
2.1. Introduction to cardiac cell therapy
Multiple trials have been initiated addressing the transplantation of
stem cell populations for cardiac regeneration. An appropriate regener-
ative cell population is critical for effective therapy. Extensive preclinical
and clinical trials have investigated a number of cell types for cardiac re-
generation including skeletal myoblasts, mesenchymal stem cells (bone
marrow derived and adipose derived), embryonic stem cells, and cardi-
ac stem cells. Althoughmost cell types have produced promising results
in vitro and in preclinical studies [10–21], and have been shown to be
safe in clinical trials, cardiac stem cells, or cardiopoietic stem cells
have shown the most promise in terms of efﬁcacy. Thus, the trend is
towards delivery of cells derived from the heart, or lineage-speciﬁed
for optimal therapy for the diseased tissue. The trials are summarised
in Fig. 1, and trials for each cell-type are described in the following
sections.
2.1.1. Bone marrow derived stem cells — heterogeneous populations
(BMMNCs)
Bone marrow aspirate or lineage-unselected bone marrow derived
mononuclear cells (BMMNCs) have been used for a signiﬁcant number
of preliminary clinical studies. These studies have consistently demon-
strated the safety and feasibility of BMMNC administration, encouraging
further investigation, but clinical beneﬁts to date have not been con-
vincing. Orlic et al. demonstrated that intramyocardial injection of
BMMNCs improved cardiac contractility and resulted in the formation
of new cardiac tissue in amousemodel of MI [10,11]. Kudo et al. report-
ed that BMMNCs could reduce infarct size and ﬁbrosis, and differentiate
into cardiomyocytes and endothelial cells [12]. However more recent
research showed that these cells likely do not differentiate into
cardiomyocytes [22]. Clinical trials such as TOPCARE-AMI [23], REPAIR-
AMI [24], BOOST [8,25] and FINCELL [26] have shown increases in left
ventricular ejection fraction (LVEF) in cell treated patients compared to
controls at time points up to 18 months. Long-term (5-year) beneﬁts
were demonstrated in the TOPCARE-AMI trial [27] but not in the
BOOST trial [28]. In contrast, the ASTAMI [29], BONAMI [30], Leuven-
AMI [31], and HEBE [32] trials showed no signiﬁcant increase in left
ventricular ejection fraction over the control group. A Phase I trial
(NCT00114452) [33]with prochymal allogeneic stem cells (Osiris Ther-
apeutics Inc.) showed an increase in LVEF at 6 months after allogeneic
BMMNC transplantation, but no improvement in patient physicalperformance, as measured by the six minute walk test, highlighting the
need for a consensus on standardized accepted metrics for cardiac cell
therapy efﬁcacy. Trials carried out by the Cardiovascular Cell Therapy
Research Network (CCTRN) indicated no clinical beneﬁt of BMMNCs in
acute myocardial infarction (AMI), where they looked at timing of post-
AMI intracoronary administration in the TIME [34] and LateTIME [35]
trials. Numerous multicentre studies are ongoing to investigate autolo-
gous bone marrow cell therapy including REVITALIZE (NCT00874354),
REGEN-AMI (NCT00765453), REPAIR-ACS (NCT00711542), SWISS-AMI
(NCT00355186) and BAMI (NCT01569178). Similarly, no clinical beneﬁt
was noted in a trial investigating transendocardial delivery of BMMNCs
for heart failure (FOCUS-CCTRN) [36], although TOPCARE-CHD [37]
showed a 2.9% increase in LVEF over base-line at 3 months. The overall
negative results of these trials have encouraged exploration of other cell
types or “next-generation” cell therapy, where cells are subjected to
screening assays to predict regenerative potential before cell transplanta-
tion [38], or cells are modiﬁed or delivered concomitantly with drugs, as
will be discussed in subsequent sections. The prevailing concept of
BMMNC efﬁciency is explained by the paracrine hypothesis, where solu-
ble factors (chemokines, growth factors, etc.) are secreted by transplanted
cells, especially in hypoxic environments, and encourage cardiac repair
[39]. This hypothesis has been supported experimentally throughdemon-
stration that conditioned media can somewhat replicate the effects of
stem cell therapy [40]. Potential mechanisms include increasing angio-
genesis, protecting endogenous cells, attuning the inﬂammatory process-
es and encouraging cell-cycle re-entry [41].
2.1.2. Puriﬁed stem cell populations: MSCs and EPCs
More recently, bone marrow aspirate has been puriﬁed by pheno-
typic features into twomultipotent cell populations; humanmesenchy-
mal stem cells (hMSCs) and endothelial progenitor cells (EPCs). Puriﬁed
sub-populations were demonstrated to show higher engraftment, and
can induce endogenous cardiomyogenesis [42]. BMMNCs have been
delivered via intracoronary injections for the treatment of acute MI,
but these puriﬁed subpopulations can be used for the treatment of
chronic ischaemia and refractory angina. Clinical trials have been initiat-
ed for both subpopulations. The POSEIDON trial compared autologous
and allogeneic hMSC transplantation in patients with ischaemic cardio-
myopathy at different doses, and showed that allogeneic cells did not
elicit donor-speciﬁc immune reactions, and that both groups favourably
affect patient functional capacity and ventricular remodelling, although
they did not increase ejection fraction [43]. The TAC-HFT trial compared
BMMNCs and hMSCs for heart failure, and reported that bothwere safe,
with a trend towards reverse remodelling and regional contractility.
Adipose tissue is also being used as a source for hMSCs. When adipose
stem cells and bone marrow stem cells were compared in a porcine
MI model, they both showed similar improvements in cardiac function
and increased capillaries in the infarct [44]. In a study by Zhang et al.
[21], adipose derived stem cells (ADSCs) transplanted into the myocar-
dial scar tissue formed cardiac-like structures, induced angiogenesis and
improved cardiac function. The APOLLO trial (NCT00442806) investi-
gated transplanting fresh adipose derived MSCs to ST-elevated MI
patients, and showed positive trends towards cardiac function, perfu-
sion and neovasculogenesis (generally attributed to EPCs) [45]. The
PRECISE trial (NCT00426868) looked at delivering adipose derived
MSCs to patients with retractable angina, and noted no improvement
in ejection fraction, but an increase in patient symptoms and exercise
tolerance [46]. ANGEL is a Phase I trial that has completed enrolment
for BioHearts Adipocell® therapy. Two Phase II studies have been initi-
ated for adipose derived stem cells using intramyocardial injection;
ATHENA (NCT01556022) for chronic myocardial ischaemia and
MyStromal Cell (NCT01449032) [47] for chronic ischaemic heart dis-
ease and refractory anginawhere cells are pre-stimulatedwith vascular
endothelial growth factor (VEGF). With regard to EPCs, early clinical
studies have pointed to symptomatic beneﬁts in patients with angina
and cardiomyopathy [48–52]. In the ACT-34-CMI trial [49] investigators
Cell
Therapy
Unselected cells Purified/ 
selected cells
Cells with
Materials
Fig. 2. Cell therapy: This ﬁgure shows different cell therapy approaches with different levels of sophistication and translational potential; unselected cells, puriﬁed cells and cells with
materials.
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using granulocyte colony stimulating factor (G-CSF) for improvingmyo-
cardial perfusion. The frequency of angina was signiﬁcantly reduced
compared to the control with the low-dose but not high-dose arms.
2.1.3. Skeletal myoblasts
Beginning almost 20 years ago, animal studies demonstrated that
skeletal satellite cells or skeletal myoblasts showed promise in their
ability to differentiate into myotubes or newmyocardium and improve
cardiac function post-infarction [53–60]. Skeletal myoblasts were
transplanted from the skeletal muscle of a patient, puriﬁed, expanded
and implanted into the heart [61]. TheMAGIC trial revealed attenuation
in LV remodelling, but no improvements in cardiac function, andwas ul-
timately terminated due to increased risk of ventricular arrhythmias
[62]. The failure to improve myocardial function may be attributed to
the inability of skeletal myoblasts to differentiate into cardiac myocytes
[63] or integrate electrically with the syncytium of themyocardium [63,
64]. Muscle derived stem cells [65] or cardiogenic muscle derived cell
populations [66] may hold promise. MyoCELL® is a skeletal muscle
myoblast cell therapy developed by BIOHEART [67] and is in Phase II/
III trials in the US (MARVEL NCT00526253) in conjunction with the
MyoCATH and MyoSTAR delivery catheters. Phase I trials and Phase II
trials in Europe showedmixed results regarding increase in left ventric-
ular ejection and clinical beneﬁt [68–71].
2.1.4. Cardiac stem cells
Cardiac stem cells or CSCs are stem cells speciﬁc and resident to the
heart. They are clonogenic,multipotent, self-renewing and can differen-
tiate into three lineages; cardiomyocytes, endothelial cells and vascular
smooth muscle cells. They express three cell-surface markers; MDR-1
(multi-drug resistant protein), C-kit (the receptor for stem cell factor),
and/or Sca-1 (Stem cell antigen 1). Three methods for isolation of
human cardiac stem cells have been described: (i) homogenizing large
pieces of cardiac tissue and selecting CSCs using antibodies (usually lim-
ited to patients that undergo cardiac interventions such as bypass or
transplant) [72], (ii) culturing a single biopsy and selecting CSCs withantibodies as a subpopulation [73] and (iii) CSCs form cardiospheres
and can be selected by exploiting this property without the use of anti-
bodies [74]. CSCs reside in stem cell niches similar to those of highly
regenerating tissues in the post-natal senescent heart, and can undergo
symmetric or asymmetric division, giving rise to more CSCs or commit-
ted cells. When the heart tissue is injured, diseased or aged, resident
stem cell niches can also be affected, so the capacity of the heart to
self-heal is affected [75,76]. C-kit+ progenitor cells are a candidate for
cell therapy and can be found in multiple species, and are reported to
be both essential and adequate for myocardial repair, without ruling
out participation of other cell types [77]. C-kit+ cells have all the afore-
mentioned properties of cardiac stem cells, and were the ﬁrst cardiac-
speciﬁc stem cell to be approved for a Phase I clinical trial SCIPIO
(NCT00474461) [78]. In the SCIPIO trial c-kit+ cells were isolated
from a biopsy from the right atrial appendage taken during bypass sur-
gery and 1 million cells were delivered (mean of 115 days after MI) via
intracoronary injection to the infarction. Investigators reported signiﬁ-
cant increases in LVEF and decreases in a scar size of N30% [78,79].
However, this is an area of signiﬁcant controversy in the literature,
and caution must be exercised with regard to the reported cardiogenic
potential of these cells. Recent work has reported that c-kit+ cells
can only generate cardiomyocytes at a functionally insigniﬁcant
level (b0.03%), and that injection into diseased heart is unlikely to be
responsible for new cardiomyocytes [80]. Other work points towards
the concept that c-kit+ precursors can generate cardiomyocytes in
the neonatal heart, but not the adult heart [81] or that in the
neonatal heart they are responsible for myocardial regeneration and
vasculogenesis, but in the adult heart they are only involved in
vasculogenesis [82], potentially explaining the reported clinical effects.
Another Phase I trial, CADUCEUS [83] examined the beneﬁt of CSCs for
heart regeneration after myocardial infarction. C-kit+ cells were har-
vested by an endomyocardial biopsy, and explants were cultured to
form cardiospheres [74,84]. Selected cardiospheres were infused into
the culprit arteries at 6 weeks to 3 months after MI (1.25–2.5 × 107
cells). Scar size and left ventricular volumes beneﬁtted from CSC thera-
py, but LVEF was not signiﬁcantly increased. Follow-up studies have
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(NCT01458405) for autologous and allogeneic CSCs, respectively.
2.1.5. Cardiopoietic stem cells
Directing the lineage of stem-cell populations towards speciﬁc or-
gans is promising, as cells can be obtained frommore abundant sources
than the target organ itself. Additionally, risks associated with biopsy of
organs and issues with poor cell yields can be eliminated. Directing lin-
eage towards speciﬁc organs was originally described for pluripotent
embryonic stem cells [85–87], but can also be applied to adult stem
cell populations, including human MSCs. When exposed to certain
growth factors to upregulate cardiogenic potential, the cells are directed
down the cardiopoietic lineage [38,88]. The C-CURE trial investigates
delivery of cardiopoietic mesenchymal stem cells to ischaemic cardio-
myopathy patients. The trial demonstrated efﬁcacy and safety of the
approach — with an increase in LVEF of 7% and positive effects on
haemodynamics and exercise tolerance [89]. Phase III trials CHART-I
and CHART-II are starting in Europe and the US. These studies further
underline the trend towards pre-conditioning cells with growth factors
and even a hybrid approach where cells are delivered with growth fac-
tors or drugs, as discussed in the following section.
2.2. Additional considerations for cell therapy
Clinical translationneeds to be the key consideration for cell therapy.
The optimal timing for cell administration and the effect of the extracel-
lular matrix must be fully understood. Studies are ongoing to elucidate
the mechanical changes in the infarct andmechanism by which the ex-
tracellular environment of the infarcted area regulates the therapeutic
potential of stem cells. In a recent study researchers isolated and charac-
terized a diseased matrix to understand the effect of changes in infarct
stiffness over time on stem cell therapy [90]. Another factor for consid-
eration is the optimal endpoints for clinical trials. Many have used
ejection fraction as a metric of functional beneﬁts, but whether this
translates into clinical beneﬁts is not fully implicit and often doesn't cor-
relate with other functional parameters such as end systolic volume. A
metric of physical performance, such as the 6 minute walk test has
been included in recent trials, which makes sense, as the ultimate goal
of such regenerative therapy is to restore the patient's exercise toler-
ance and overall lifestyle to the pre-disease condition. Furthermore,
the timing of this type of functional testing is important, and in order
to evaluate the contribution of regeneration, a 6 minute walk test atTable 1
Fold-increase in cell retention over intramyocardial saline delivery reported with various
injectable hydrogels.
Study Hydrogel Time(s)
of
analysis
Fold-increase in
retention compared
to saline control
Zhang et al. [105] PEGylated Fibrin + HGF 4 weeks 1.3 for unaltered gel
15 pro-survival HGF
included
Yu et al. [106] Alginate Microspheres 24 h 1.3 (*NS)
Christman et al.
[107]
Fibrin 5 weeks ~2
Habib et al. [108] PEG diacrylate 48 h ~2.5
Wang et al. [100] PEG based 4 weeks 2.5
Martens et al. [109] Fibrin 90 min 1.77
Liu et al. [98] Chitosan/β-GP/*HEC 24 h 1.5
4 weeks 8
Lu et al. [110] Chitosan/β-GP/*HEC 24 h 1.75
4 weeks 2
Wang et al. [99] Chitosan/β-GP/*HEC 1 day ~1.5
1 week ~1.9
2 weeks ~2
4 weeks Presence of cells in
chitosan group, none
in control
*HEC = Hydroxy-ethyl cellulose. *NS = Not Signiﬁcant.12 months should be employed to draw meaningful conclusions
(Fig. 2).
2.3. Cells with biomaterial carriers
One of themajor challenges in the clinical translation of cell therapy
is delivering and retaining viable cells in the heart tissue. The develop-
ment of cell therapy as a feasible therapeutic option is dependent on
methods to enable viable cells to reside in infarcted tissue and exert
therapeutic effects for extended periods. In cell therapy, isolated cell
suspensions in saline are usually administered systemically via intrave-
nous infusion or directly injected into the injured heart via the myocar-
dium, or perfused into the coronary arteries or veins. The cell therapy
clinical trials discussed in previous sections have primarily utilised
such simple cell delivery strategies. Saline solutions don't have the
capacity to localise and retain cells at the target site, and do little to
cater for the unique requirements of living cells with regard to provid-
ing biological cues to inﬂuence cell viability, behaviour and fate [8,33].
Poor cell retention is likely to be a major contributing factor in the fail-
ure of cell-based therapies for MI to achieve consistent and substantial
efﬁcacy to date [3,91]. Among the possible mechanisms underlying
the phenomenon of poor retention are exposure of cells to ischaemia
and inﬂammation, mechanical washout of cells from the beating heart,
ﬂushing by the coronary vessels, leakage of cells from the injection
site and anoikic cell death [92–94]. To address these issues there has
been a signiﬁcant amount of preclinical research into material-based
cell therapy for cardiac repair. Delivered biomaterials can produce better
spatial distribution and potentially less problemswith arrhythmogenicity
than simple saline injection techniques. A biomaterial scaffold can pro-
vide a surrogate ECM for encapsulated cells to enhance cellular viability
and enable physical retention at the infarct site. Biomaterials can pro-
vide protection from noxious insults like ischaemia and inﬂammation
and reduce cell death due to anoikis. Cell-loaded biomaterials address
the issue of mechanical dispersal of cells from the injection site, which
is a major source of cell loss within themyocardium and several studies
have shown that biomaterial delivery vehicles can enhance myocardial
cellular retention [95–97]. In short, biomaterials can help to deliver
more cells to the target site, keep cells localised and viable, and enhance
sustained production of beneﬁcial paracrine factors at the target site. To
date, there exist twomajor biomaterial approaches to achieving cellular
delivery to the myocardium, namely cell-loaded injectable hydrogels
which encapsulate cells and polymerize in situ in the myocardial wall,
or preformed cell-seeded scaffolds which are afﬁxable to the epicardial
surface [7], and both of these approaches will be addressed brieﬂy here.
2.3.1. Injectable hydrogels
Hydrogels can typically be injected via three routes: intracoronary,
epicardially or transendocardially. Such hydrogels have the potential
to rapidly exploit advancements in catheter technology for minimally
invasive delivery, reduced cost, shorter hospital times and potential for
multiple spatial and temporal administrations. To ensure injectability
thematerial and cellsmust facilitate loading into a catheter, the solution
must gel quickly at the site (but avoid premature gelation and catheter
blocking) and the gel must remain structurally sound for the course of
the therapy (to avoid embolization), and must degrade after cell thera-
py without producing toxic byproducts. The gel should also have
mechanical properties suitable for supporting the ventricular wall — it
must be robust, and endure the fatigue cycling of the heart throughout
the course of cell therapy. The increase in cell retention achievable can
become more dramatic over time. For example, Liu et al. reported a
1.5-fold increase in cell retention of adipose-derived stem cells encap-
sulated in chitosan/β-glycerophosphate/hydroxy-ethyl cellulose
(chitosan//β-GP/HEC), 24 h post-administration via intramyocardial
injection, compared to cells delivered in saline [98]. However, an 8-
fold increase in retention was observed in hydrogel-injected animals
at day 28, which was likely related to a greater loss of cells from saline
Cell Free
Therapy 
Acellular 
Biomaterials Small
Molecules
Growth 
Factors
Proteins
RNA 
Therapy
Fig. 3. Cell-free therapy: Two types of cell-free therapy are discussed here; material based cell free-therapy and endogenous targeting, including RNA therapy, growth factors and proteins
and small molecule therapy.
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tosan not only improves retention of cells over time but also enhances
cardiac differentiation of brown adipose derived stem cells and enhances
functional improvements in the rat model [99]. Wang et al. used an α-
cyclodextrin/poly(ethylene glycol)–b-polycaprolactone-(dodecanedioic
acid)-polycaprolactone–poly(ethylene glycol) (MPEG–PCL–MPEG)
hydrogel for bone marrow stem cell delivery, and showed improved re-
tention in gel-injected animals, correlating with improved left ejection
function and attenuation of scar expansion and left ventricular dilation,
corroborating the hypothesis that biomaterial delivery can result in tan-
gible enhancements in efﬁcacy [100]. Collagen and laminin are themain
components of myocardial extracellular matrix (ECM) and so can sup-
port cardiomyocyte attachment and elongation but the shape and
dimensions of collagen and laminin biomaterial constructs have not
yet been optimised. Future research may include designing 3-D shapes
for these hydrogels, for example a collagen type 1 tubular scaffold has
also been investigated [101], and shape memory injectable gels have
been developed and should be considered for cardiac cell therapy
[102,103]. An emerging technique for combining the advantages of
hydrogel approaches with controllable, tailored tissue shape and size
is bioprinting, enabling precise control over where cells are in the con-
struct and the overall construct architecture to affect a particular cell
fate or behaviour (Table 1) [104].
2.3.2. Preformed porous scaffolds
Porous or ﬁbrous preformed scaffolds are themost commonway for
creating 3D constructs for cell delivery. In many cases, cells are grown
on these constructs pre-implantation and patches are surgically
attached to the epicardial surface. Leor et al. used a 3D alginate scaffold
to construct a bioengineered cardiac graft in a ratmodel of MI [111,112]and subsequently optimised it for cell seeding and distribution. A colla-
gen patchwas also used as a successful delivery vehicle for humanmes-
enchymal stem cells and human embryonic stem cell derived-
mesenchymal cells for cardiac repair [113,114]. Cell attachment is an
important consideration in such constructs and they can be modiﬁed
with short peptides such as Arg-Gly-Asp (RGD); a peptide sequence de-
rived from the ﬁbronectin signalling delay [115–119]. The selection,
density and patterning of binding sequences depend on the cell type
to be seeded on the matrix, and the natural ECM environment. Here,
we discuss porous scaffolds as carriers for cells to improve retention,
but a large volume of work has explored engineered heart tissue, so
the reader is referred to a comprehensive review [120] for more detail
on this. As an example, pre-conditioning of engineered heart patches
by cyclical mechanical stretch has shown to improve morphology and
contractile function of patches [121–128]. In a recent study electrospun
poly(e-caprolactone)/gelatin nanoﬁbres were formed into a nanoﬁbrous
patch to act as an improved method of cell retention (grafted MSCs
resulted in angiogenesis and facilitated cardiac repair) [129] as well as
providing mechanical support to the wall and acting as a ventricular
restraint, as discussed in the following section. The nanoﬁbrous PG-
cell scaffold produced improvements in cardiac function (increase in
fractional shortening and ejection fraction, reduction in scar size and in-
crease in thickness in the infarcted area). Combinations of cell-loaded
gels and patches have been explored. Soler-Botija et al. describe prelim-
inary work on a ﬁbrin loaded patch and an engineered bioimplant
(combination of elastic patch, cells and peptide hydrogel (Puramatrix,
Bedford, MA)) [130]. Electrical stimulation combined with 3D cell culti-
vation has also been explored. Nunes et al. describe the Biowire for plu-
ripotent stem cell-derived cardiomyocytes, consisting of a collagen gel
surrounding an electrically stimulated silk suture. These biowires had
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nization and conduction velocity (Fig. 3) [131].
3. Cell-free approaches
Cell-based strategies for cardiac repair involve delivering cells with
potential for repair or regeneration to ischaemic or damaged areas of
the heart. Despite the initial expectation regarding the cardiogenic
potential of transplanted cells, in most studies the number of delivered
cells that actually differentiate into cardiomyocytes is not large enough
to account for observed clinical beneﬁts, primarily due to low engraft-
ment. The paracrine hypothesis may explain this, whereby released
soluble factors from transplanted cells aid in regeneration [39,132].
There are a number of proposed mechanisms for such paracrine effects
including increased angiogenesis, control of inﬂammatory responses,
promotion of cardiac cell cycle re-entry and recruitment of endogenous
stem cells, suggesting that paracrine targeting of endogenous cells may
underlie many of the effects of cell therapy [41]. Similarly, delivery of
cells has also been shown to produce mechanical reinforcement to the
infarct scar area [133]. The ﬁeld has undergone a paradigm shift, and
investigators are renouncing the notion that therapy must be ﬁxated
solely around cells. Instead strategies such as acellular material-based
approaches to produce mechanical reinforcement and tissue bulking
in the myocardial scar and endogenous cell targeting through bioactive
molecule delivery are subjects of extensive research to complement
cell-therapy or to stand alone as cell-free therapy. Acellular strategies
to cardiac repair have inherent advantages in that the lack of a required
cell source could aid clinical translation.
3.1. Acellular material-based scaffolds
Material-based approaches target the important mechanical chang-
es that occur post-myocardial infarction (or in chronic heart failure)
resulting in ECM breakdown, geometric changes, LV dilation, stretched
cardiomyocytes that can't contract, a growing borderzone and a spher-
ical, thinning left ventricular wall [134–136]. Surgical ventricular resto-
ration [137] (SVR), endoventricular circular patch plasty technique (Dor
procedure) [138], partial ventriculectomy (Batista procedure) [139] and
passive restraint devices such as the Acorn CorCap™ device [140,141],
the Paracor Medical HeartNet restraint device [142], and the Myocor®
coapsys device [143] all share the primary goal of reducing ventricular
wall stress, and restoring left ventricular geometry. According to
LaPlace's lawT=P · R/t, where T, in this instance, is tension in themyo-
cardial wall and varies proportionally to P (intraventricular pressure)
and R (radius of curvature) and is inversely proportionally to t (myocar-
dial wall thickness). By thickening the wall with a reinforcing material,
stress can be decreased in the wall, especially around the infarct border
zone [144]. Acellular injectable hydrogels and epicardial patches can be
used to provide this tissue bulking wall reinforcement. If engineered to
have speciﬁc biomechanical properties, this acellular material can pro-
mote the endogenous capacity of the infarcted myocardium to attenu-
ate remodelling and improve heart function following myocardial
infarction [145]. The elastic modulus can be tailored to match that of
healthy myocardium or can be manufactured to have a higher elastic
modulus to enhance tissue reinforcement [146], and numerical based
simulations are valuable in predicting the response [144]. An optimal
biomaterial should be able to balance the high forces that occur at the
end of contraction in order to prevent or reversemaladaptivemodelling
[146]. The scaffold should be able to transfer the stress from the infarct-
ed myocardium and border zone, and if the scaffold is biodegradable,
cellular inﬁltration, vascularisation and formation of tissue should be
sufﬁcient to transfer the stress from the scaffold to thenewmyocardium
before degradation. Injectable biomaterials used for acellular tissue
reinforcement in animal models include ﬁbrin [107,147], alginate
[148–151], collagen [152], chitosan [98,110], hyaluronic acid [146,
153], matrigel [124,154], polyethylene glycol (PEG)-based materials[155–157], acrylamides [158,159] and composites [160] of these mate-
rials. Both small animal studies [148,150] and large animal models
[149,160–162] have demonstrated beneﬁt of this tissue bulking
effect. For example, a biodegradable, thermoresponsive hydrogel
for bulking of the ventricular wall based on copolymerization of
N-isopropylacrylamide (NIPAAm), acrylic acid (AAc) and hydroxyethyl
methacrylate-poly(trimethylene carbonate) (HEMAPTMC) was de-
signed and characterized, and produced an increase in wall thickness
and capillary density, and ingrowth of contractile smooth muscle cells,
thus offering a potential attractive biomaterial therapeutic strategy for
ischaemic cardiomyopathy [158].
In addition to injectablematerials, patches can be placed epicardially
in order to provide wall thickening and reinforcement. Elastic patches
such as polyester urethane urea have demonstrated an ability to pro-
duce an increase in fractional area change, and an attenuation of
ventricular dilation in a rat MI model [163]. Engineered scaffolds or
patches, such as a recently reported type 1 compressed collagen patch
[145] can provide mechanical support to infarcted tissue, reducing dila-
tion and ﬁbrosis, increasing wall thickness and also increasing angio-
genesis at the infarct zone and in the patch and border zone. This can
lead to increased oxygen delivery and reduction in ischaemic tissue,
and generation of new cardiomyocytes [145]. Clinically, an injectable
hydrogel called Algisyl-LVR™ (LoneStar Heart, Inc., CA) has been used
in a recently initiated Phase II trial AUGMENT-HF (NCT01311791). Cir-
cumferential intramyocardial injections of the alginate hydrogel remain
in the heart (at the mid-ventricular level) as a permanent implant with
the goal of increasing wall thickness, reducing wall stress and restoring
ventricular geometry. Pre-clinical studies and a pilot study [164] show
that the device has promise for decreasing ventricular volumes, increas-
ing ejection fraction and wall thickness and decreasing myoﬁbre stress
at six months [164]. The AUGMENT-HF trial will evaluate the safety
and efﬁcacy of Algisyl-LVR™ as a method of left ventricular augmenta-
tion in patients with dilated cardiomyopathy, with a primary efﬁcacy
endpoint of change in peak VO2 (maximum oxygen uptake) from base-
line to sixmonths. This trial should provide some insight into the clinical
beneﬁts of the therapy. Another injectable alginate implant that has
moved to clinical study is Bioabsorbable Cardiac Matrix (BCM), also
known as IK-5001. After encouraging animal studies [148], recruitment
is ongoing for PRESERVATION I (NCT01226563); a trial which investi-
gates an in situ forming version of this hydrogel. An aqueous combina-
tion of sodium alginate and calcium gluconate is delivered in a bolus
intracoronary injection, and into the heart muscle to form a ﬂexiblema-
trix that supports the heart physically and eventually dissipates and is
excreted through the kidneys. The primary efﬁcacy outcome measure-
ment is left ventricular end diastolic volume index (LVEDVI).
The current limitations of acellular biomaterials are that optimal
design parameters for therapeutic efﬁcacy, including stiffness, degrada-
tion rate and bioactivities have yet to be determined. The experimental
results in the literature reveal a complex biological and mechanical
interaction between material and tissue. Experimental assessment of
tissue bulking agents is mainly undertaken using a rat model of MI,
which is not as clinically representative as a large animal model in
terms of injection volume, injection method and volume of left ventri-
cle. Injection time and data collection time also vary in these studies
[165]. Further work is warranted to fully understand the speciﬁc mech-
anisms behind reported functional improvements. Only a small number
of studies have directly compared different acellular biomaterials [166,
167], and the ideal acellular material properties have yet to be identi-
ﬁed. It remains challenging to distinguish beneﬁts resulting from chang-
ing the mechanical environment or beneﬁts resulting from cardiac
remodelling that is simultaneously occurring [168]. The in situ gelation
rate of injectables must be rapid to avoid loss of material, but rapid
gelation can make catheter delivery difﬁcult. Lack of vascularisation in
3D scaffolds may also represent a limitation if scaffolds are intended
for cell ingrowth and not just as a tissue bulking material. Cell survival
may only be possible at the peripheries of 3D constructs, without
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may be a decreased production of factors that would promote vessel
sprouting. Provided tissue replacement is eventually envisaged, tissue
ingrowth and vascularisation must be sufﬁcient for stress transfer to
newly generated myocardium before degradation, and the timing of
degradation to match tissue ingrowth will be critical to successful
translation. If the purpose of the acellular biomaterial is to provide an
environment for endogenous cells to proliferate and regenerate, endog-
enous cell numbers may not be high enough to initiate desired cell pro-
cesses. Acellular scaffolds cannot fully function as viable cardiac tissue
replacements, and are not fully biomimetic, potentially limiting the
full potential of endogenous cells to recover through inﬁltration of the
implant. Acellular constructs negate the opportunity to pre-condition
to enhance functionality and integrationwith cardiac tissue. For example,
cell-loaded scaffolds can undergo mechanical and electrical pre-
conditioning that may result in a mature cardiac structure, higher force
generation and electrical coupling in the heart [122,127,128,170,171].
Although true of all biomaterials, limitations for synthetic materials in-
clude difﬁculties with scale-up of complicated chemical reactions and
lack of innate bioactivity, and with natural biomaterials limitations in-
clude difﬁculties with regulatory approval and batch-to-batch variability
[133]. Finally, degradable materials can cause an inﬂammatory response
and phagocytosis [168], the effects of which are not fully characterized,
and are currently reported to have beneﬁcial [158] and counter-
productive effects [155].
3.2. Endogenous targeting
3.2.1. Small molecules
Small molecule drugs represent a promising therapeutic deliverable
for the treatment of ischaemic cardiomyopathy. These compounds are
often inexpensive to make and store. Advances in synthetic chemistry
mean that large libraries of structurally diverse molecules can be pro-
duced and screened for efﬁcacy in modulation of a speciﬁc molecular
target. Similarly, a library of smallmolecules can be screened in a biolog-
ical system to determine novel drug targets and elucidate previously
unknown signalling systems implicated in myocardial disease. Struc-
ture activity relationship data can enable molecular modiﬁcation to
optimise speciﬁcity, stability and efﬁcacy. Such approaches are of dis-
tinct utility in clinical development. Small molecule drugs are currently
at an early stage of development for the purpose of myocardial regener-
ation (for review see Jung andWilliams [172]). Here, we discuss a con-
cise selection of candidate drug classes, with a particular focus on
advanced delivery to improve treatment outcomes.
3.2.1.1. Prostaglandins. Prostaglandins are endogenous small-molecule
fatty acid derivatives which mediate a variety of physiological effects.
Prostaglandin E2 and Prostaglandin I2 have a regenerative role in the
ischaemic myocardium and may have therapeutic potential post-MI.
3.2.1.2. Prostaglandin E2 (PGE2). Hsueh et al. demonstrated that daily
intraperitoneal administration of PGE2 enhanced cardiomyocyte re-
plenishment at the infarct border zone in a murinemodel of MI. Prosta-
glandin I2 (PGI2) did not produce such effects, in this study. PGE2
increased the presence of Sca-1+ cells and regulated their potential
for a cardiomyogenic differentiation, suggesting that PGE2 could
activate and mobilise the endogenous CSC population. In addition,
PGE2 treatment rescued the ability of old mouse hearts to replenish
cardiomyocytes at the infarct border [173]. PGE2 is FDA approved for in-
duction of labour, and so possesses signiﬁcant translational potential.
However, PGE2 is rapidly metabolised in vivo and so repeated dosing
was necessary in this study, which utilised a simple systemic route of
administration. This underpins the need for protective encapsulation
and delivery for long-term treatment and/or synthesis of more stable
prostaglandin mimics.3.2.1.3. Prostaglandin I2 (PGI2). PGI2 is a vasodilator and potent anti-
coagulant and has been FDA approved for the treatment of hyperten-
sion. Like PGE2, PGI2 has a short half-life in vivowhich is decreased in
conditions of myocardial infarction [174]. Ishimaru et al. delivered
ONO1301, a stable small molecule PGI2 agonist on an epicardial colla-
gen patch to hamster hearts in a model of dilated cardiomyopathy
(but the observed therapeutic actions are likely also applicable to
acute MI), and found that ONO1301 treatment upregulated myocardial
expression of cardioprotective HGF, VEGF, SDF-1 and G-CSF. ONO1301
concentrations were found to be signiﬁcantly higher in left ventricular
tissue than in systemic circulation for as long as two weeks after treat-
ment, highlighting the importance of local delivery and sustained
release. ONO1301 treatment preserved cardiac performance, in-
creased myocardial vascularisation, reduced ﬁbrosis and prolonged
survival [174]. In a second study, Nakamura et al. encapsulated
ONO1301 in polylactic-co-glycolic acid (PLGA) microspheres which
produced a sustained release of drug for 10 days. The microspheres
were injected intramyocardially in a mouse model of acute MI and
increased local HGF and VEGF expression, increased vascularisation
of the infarct border zone by day 7, decreased left-ventricular dilata-
tion and improved survival by day 28. ONO1301 was well tolerated
when delivered intramyocardially in PLGA microspheres. A Phase I
clinical trial, where ONO1301 was administered orally was discontinued
due to diarrhoea in participants and systemic administration has been
shown to produce hypotension in experimental animals, highlighting
the importance of localised and controlled delivery in realising the full
potential of a given therapeutic strategy and avoiding off-target effects
[175].3.2.1.4. Pyrvinium Pamoate. Pyrvinium Pamoate (PP) is an FDA approved
anthelmintic drug, which inhibits NADH-fumarate reductase activity
essential for the anaerobic respiration of parasitic worms. Murakoshi
et al. postulated that the administration of PP could produce a differen-
tial cytotoxic effect in ﬁbroblasts which proliferate in the myocardial
scar after infarct, and are reliant on anaerobic respiration in ischaemic
conditions, and hence enable anti-ﬁbrotic therapy. PPwas administered
orally, daily, beginning at 24 h after permanent left coronary artery liga-
tion (when the cardiomyocytes in the infarct areawere likely dead) in a
mousemodel of MI. There was a signiﬁcant reduction in the presence of
ﬁbroblasts in the infarct and border regions by seven days and fourteen
days and LVEF increased in PP treated animals. The authors also report
an increase in scar vascularisation, which they attribute to the permis-
sive microenvironment created by inhibition of ﬁbrosis. PP therapy
was well tolerated [176].
This is in contrast to a different study where Saraswati et al. admin-
istered PP via a single intramyocardial injection in a saline carrier at the
time of coronary artery ligation in a mouse model of MI, and observed a
signiﬁcant increase in animal mortality upon PP treatment. It is likely
that administration of PP at this early stage enhanced cardiomyocyte
death in ischaemic conditions, resulting in larger infarcts and mortality,
and highlights the importance of time of dosage. Surviving animals did
not display a signiﬁcant enhancement of cardiac regeneration or reduc-
tion of ﬁbrosis. A once off injection of PP in salinemay not have enabled
signiﬁcant myocardial retention of the drug up to the time of initiation
of ﬁbrosis. Therefore, utilisation of a biomaterial carrier, administered
at a minimum of 24 h post-infarct, which facilitated sustained release
may have ameliorated these results. Similarly, stimulus responsive
nanoparticles, tuned to deliver drug in a ﬁbrotic environment or at the
time of initiation of ﬁbrosis may have improved treatment outcome
[177].While PP treatmentwaswell toleratedwhen administered orally,
the risk for cytotoxicity to cardiomyocytes in the border zone where
perfusion is limited, or CSCs naturally present in a hypoxic niche, may
justify the use of targeted nanoparticulate carriers to ensure increased
speciﬁcity for ﬁbroblasts and decreased risk for toxicity in future studies
[178].
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bound peptidase which cleaves SDF-1. Pharmacological inhibition of
DPP-IV aims to stabilise myocardial SDF-1 after MI, thereby enhancing
recruitment of CXCR4+ circulating stem cells to effect regenerative ef-
ﬁcacy. Zaruba et al. administered either Diprotin A, a small molecule
DPP-IV inhibitor (twice daily systemic administration), G-CSF, to mobi-
lise circulating progenitors or a multimodal administration of both in a
mouse MI model. Combining G-CSF mobilisation and DPP-IV inhibition
resulted in an increase in CXCR4+ cell homing to the myocardium,
attenuation of infarct remodelling, neovascularisation in the infarct
border zone, enhanced myocardial function and increased survival.
Only the combination of Diprotin A and G-CSF treatment signiﬁcantly
attenuatedmyocardial remodelling, highlighting the potential of multi-
modal therapeutic strategies [179]. In addition, Theiss et al. demonstrat-
ed that a G-CSF/Diprotin A multimodal therapy signiﬁcantly increased
numbers of resident CSCs [180]. Given that it was necessary to adminis-
ter Diprotin A twice daily to maintain efﬁcacious concentrations within
the myocardium, a sustained release formulation could greatly aid
clinical translation. A Phase III clinical trial with another DPP-IV inhibi-
tor, Sitagliptin, which has been approved for the treatment of hyper-
glycaemia, in conjunction with G-CSF administration in patients with
acute MI reported that the approach was well tolerated and appears
feasible, but has yet to publish efﬁcacy data [181].
3.2.2. RNA therapeutic strategies
3.2.2.1. Modiﬁed messenger RNA. A novel therapeutic strategy which has
emerged recently is the delivery of modiﬁed messenger RNA (modRNA).
Kormann et al. demonstrated that a collection of nucleotide modiﬁca-
tions inhibited mRNA interaction with certain toll-like receptors, re-
duced immunogenicity and consequently enhanced stability when
the modRNA was administered to mice. An intramuscular injection
of modRNA produced a signiﬁcant increase in target protein produc-
tion in vivo. modRNA delivery to the lungs ameliorated a fatal genetic
deﬁciency in mice despite only producing a very transient protein ex-
pression [182]. Warren et al. used modRNA delivery to create induced
pluripotent stem cells, demonstrating that the transient expression of
target proteins achievable could exert lasting effects on cell fate and
differentiation [183].
Zangi et al. showed that modRNA encoding VEGF could transfect
adult rat cardiomyocytes with a high efﬁciency (68%), using Lipofecta-
mine, a commercially available transfection agent. The translational po-
tential of Lipofectamine is unclear, however, since some authors have
reported very low transfection efﬁciencies in large animalmodels or sig-
niﬁcant cytotoxicity in vitro [184,185]. One injection of modRNA/Lipo-
fectamine transfected a signiﬁcant portion of the mouse myocardium
(25% of the left ventricle). Transgene expression peaked at 18 h and
returned to baseline at 2–3 days, in contrast with DNA/Lipofectamine
which peaked at 72 h and maintained high levels of expression for
10 days. VEGF modRNA/Lipofectamine was administered to infarcted
mouse hearts, in comparison with VEGF plasmid DNA. Both VEGF DNA
and VEGF modRNA increased vascular density in the infarct region but
vessels produced by VEGF DNA were leaky, contributing to oedema
which likely resulted in an observed increase in short-term mortality
in VEGF DNA treated animals when compared to untreated controls.
In contrast, modRNA VEGF treated animals showed decreased long-
term mortality and improved cardiac function when compared to
untreated controls, highlighting the importance of expression kinetics
on functional outcome. VEGF modRNA treatment also upregulatedWt
1, an epicardial cardiac progenitor marker, in the infarct region, and
in vitro data suggested that VEGF modRNA induced this cell type to
undergo an endothelial differentiation, which may have contributed to
treatment outcome [186].
The use of modRNA as a deliverable therapeutic confers several ad-
vantages over more conventional DNA therapy. Cytosolic expression
avoids the risk of insertional mutagenesis associated with DNA therapy.A transient, pulse-like expression more closely mimics endogenous
paracrine signalling, in which sustained, high levels of expression over
long periods, as produced with certain methods of DNA delivery, do
not occur. Rather, a transient, strong signal, which is spatiotemporally
controlled to act in the time and place it is required, is likely to be
more efﬁcacious and avoid undesired effects. While Zangi et al. has
clearly demonstrated elements of this concept, further investigation
intomore clinically translatable nanoparticulate delivery vectors (as op-
posed to Lipofectamine) or localised therapy involving a biomaterial
carrier will aid in unlocking the full potential of this technique. Such
approaches may enable greater myocardial targeting and retention
and spatiotemporal presentation of modRNA to maximise efﬁcacy.
modRNA therapy is currently in its infancy, and further investigation
with other target genes to produce myocardial regeneration or offset
the effects of ischaemic damage in vivo is warranted.
3.2.2.2. MicroRNA targeting. MicroRNAs (miRs) are endogenous, non-
coding strands of RNA of around only 22 nucleotides in length. miRs
are effectors of epigenetic regulation of protein expression, whereby a
single miR demonstrates binding afﬁnity for complementary oligonu-
cleotide sequences in an array of mRNA targets, resulting in an inhibi-
tion of mRNA translation and/or mRNA degradation. Given that one
miR typically hasmanymRNA targets,miR-mediated changes in protein
synthesis are involved in a variety of complex intracellular signalling
and modiﬁcation of miR activity can have signiﬁcant and multifaceted
effects on cell phenotype.
miRs represent an attractive therapeutic target since they are exten-
sively involved in cardiac development and postnatal disease processes
including ventricular remodelling and ﬁbrosis following infarction and
processes with therapeutic applicability in acute infarction such as an-
giogenesis or myocardial regeneration (for review see Fiedler and
Thum [187]). Strategies tomodifymiR activity can take two forms— up-
regulation of miR expression via transfection or viral transduction of
target cells with a functional copy of a miR (a miR mimic), effectively
inhibiting target protein expression, or inhibition of endogenous miR
activity via complementary binding to synthetic anti-sense miRs or
antagomirs, leading to an upregulation of target protein expression.
Here, we highlight a concise selection of promising miR targeting strat-
egies with different modes of action and discuss methods to enhance
the delivery of miR to the infarcted heart.
Eulalio et al. undertook a high-throughput screening analysis of 875
miR mimics to identify 2 candidates (miR-590-3p and miR-199a-3p)
which enabled the re-entry to cell cycle and proliferation of post-natal
rat cardiomyocytes. These miRs were then delivered via intramyocardial
injection of an adeno-associated viral vector to the infarcted mouse
myocardium in vivo and signiﬁcantly enhanced LVEF, increased wall
thickness and reduced infarct size, primarily by stimulating cardio-
myocyte proliferation [188]. Bonauer et al. demonstrated that miR-
92a was expressed in endothelial cells and overexpression of this
miR suppressed a variety of angiogenic processes in vitro. Conversely,
a miR-92a antagomir enhanced angiogenesis in vitro and increased
vascularisation of infarcted myocardium, reduced infarct size and en-
hanced cardiac function in a mouse model of acute MI, when admin-
istered intravenously. A panel of miR-92a target genes involved in
vessel growth and development were identiﬁed [189]. Boon et al. de-
termined that miR-34a demonstrated an increased expression in aged
rat hearts which was related to age related decline in cardiac func-
tion. A miR-34a antagomir inhibited H2O2-mediated apoptosis in rat
neonatal cardiomyocytes in vitro, and enhanced cardiac function, reduced
cardiomyocyte apoptosis and enhanced vascularisation in amousemodel
of acute myocardial infarction, when administered intramyocardially
[190]. Hu et al. demonstrated that HL-1 cardiomyocytes transduced
with miR-210 increased expression of pro-angiogenic growth factors
and reduced caspase activity under hypoxic stress. When delivered
intramyocardially via aminicircle non-viral vector in amouse acutemyo-
cardial infarction model miR-210 reduced the presence of apoptotic cells
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ventricular function. A panel of pro-angiogenic and anti-apoptotic miR-
210 target genes were identiﬁed [191].
While these studies have demonstrated the preclinical potential of
miRs for myocardial regeneration, signiﬁcant hurdles to clinical transla-
tion remain. miRs not only represent a potentially powerful target to
exert desired changes in cellular behaviour but also come with the
risk of unpredictable off-target effects. Multiple target genes are con-
trolled by a given miR, resulting in complex pharmacodynamics in
both target and non-target tissues.miR delivery poses a challenge as un-
modiﬁed miRs are rapidly degraded by systemic nucleases, may pro-
voke an immune response and demonstrate low or unpredictable
uptake by target cells. Signiﬁcant modiﬁcation of miRs to enhance sta-
bility has been achieved but sometimes at the cost of decreased speciﬁc-
ity [192]. Therefore, targeted delivery of miR therapeutics to the
myocardium utilising local delivery coupled with nanoparticulate and/
or biomaterial encapsulation is of the utmost importance.
The majority of studies investigating miR therapy for MI have used
methods of miR delivery such as intramyocardial injection of viral
vectors or simple systemic delivery of unencapsulated antagomirs.
Such approaches not only provide a proof of concept for miR
regenerative efﬁcacy in the myocardium, but also pose translational
hurdles such as safety concerns and lack of speciﬁcity formyocardial tis-
sues. A range of nanoparticulate delivery vectors have been investigated
for the targeted delivery of miRs, in a variety of different diseasemodels
outside of the cardiovascular ﬁeld, with varying degrees of success and
translational potential, including viral vectors, Poly(lactide-co-glycolide)
(PLGA) particles, dendrimers, lipid based systems, Polyethylenimine
(PEI)-based delivery systems and microvesicles such as exosomes
(reviewed by Zhang et al., Muthiath et al. and Chistiakov et al.
[193–195]). Gill et al. showed that ultrasound responsive microbubbles
could transfect HL-1 cardiomyocytes with miR-133 upon application of
ultrasound, which reversed cardiomyocyte hypertrophy. Such an
approach could facilitate systemic delivery, but mediate miR uptake and
expression only in tissues which are exposed to an externally applied
ultrasound ﬁeld [196]. Delivery of miRs in biomaterial carriers has also
shown promise. Monaghan et al. determined that a collagen scaffold
produced a sustained, bioactive release of miR-29B, which reduced mal-
adaptive remodelling in a rat wound model [197]. In addition, local miR
delivery in an injectable hydrogel has been shown to be an effective ther-
apeutic strategy [198]. However, these approaches remain underexploit-
ed in theﬁeld ofmiR therapy formyocardial regeneration and their future
exploration may provide more translatable, safer and efﬁcacious thera-
peutic strategies.
3.2.3. Direct reprogramming
A novel approach to effecting myocardial regeneration involves di-
rect reprogramming of cardiac ﬁbroblasts to functional cardiomyocytes
or cardiac progenitor cells. Due to the limited regenerative potential of
cardiomyocytes, the majority of the myocardial scar after MI is com-
posed of ﬁbroblastswith no ability to contribute to the contractile activ-
ity of themyocardium. This technique involves therapeutic deliverables
which aim to convert cardiac ﬁbroblasts to cell types which can ulti-
mately contribute to cardiac output. This has been investigated using
several different approaches, including over-expression of cardiac tran-
scription factors and delivery of microRNAs or small molecule drugs.
Here, we discuss a concise selection of studies with a view to investigat-
ing clinical potential and suggesting scope for improvement using
advanced delivery.
Recent research has identiﬁed sets of genes which, when over-
expressed, can facilitate a direct reprogramming of cardiac ﬁbroblasts
to cardiomyocytes, while bypassing a pluripotent stem cell state (and
the potential concomitant risk of tumour formation) [199]. Such
transdifferentiation has been demonstrated in vitro [200] and has also
shown clinical potential in vivo. Qian et al. reported that intramyocardial
injection of three transcription factors, Mef2c, Tbx5, and myocardin(GMT) encoded within retroviral vectors, resulted in minimal cardio-
myocyte viral infection but signiﬁcant transduction of ﬁbroblasts in
the myocardial border region of the infarcted mouse heart. 35% of
cardiomyocytes in the infarct border zone were newly generated upon
treatment and GMT delivery resulted in a decrease in infarct size and
produced modest improvements in cardiac function [201]. Song et al.
delivered GMT plus an additional factor, Hand2 (GHMT), via a retroviral
vector through an intramyocardial injection in a mouse MI model and
determined that GHMT-treated animals had an LVEF of 49% compared
to an untreated LVEF of 28%, which corresponded to twice the improve-
ment of the controls and which persisted for up to 12 weeks [202].
Jayawardena et al. transfected murine cardiac ﬁbroblasts with a com-
binationofmiRs 1, 133, 208 and499 and reported transdifferentiation to a
cardiomyocyte-like cell in vitro. The addition of a small molecule, JAK
inhibitor 1, increased the efﬁciency of reprogramming 8–10 fold demon-
strating the potential for small-molecule enhancement of this process.
The miR cocktail was delivered intramyocardially via a lentiviral vector
in amousemodel of MI, and the results suggested that cardiac ﬁbroblasts
underwent a cardiomyocyte differentiation in situ but the authors did not
investigate or report any potential effects treatment had on cardiac func-
tion [203]. In a recent study,Wang et al. utilised a small-molecule cocktail
to reduce the number of genetic manipulations required to produce
transdifferentiation of mouse ﬁbroblasts to beating cardiomyocytes to
just one— overexpression of Oct4. Cells passed through a cardiac progen-
itor stage during this transdifferentiation. Further development of this
approach could lead to a fully pharmacological reprogramming, which
could potentially circumvent some of the safety concerns of genetic
manipulation. However, Wang et al. did not investigate this approach
in vivo [199].
Clinical translation of ﬁbroblast reprogramming techniques could be
of signiﬁcant therapeutic value. Direct reprogramming is a recent con-
cept and consequently the majority of studies to date have served to
provide a proof of concept, without signiﬁcant focus on translational
delivery approaches. As this ﬁeld evolves,more clinically relevant deliv-
ery approaches and therapeutic deliverableswill be explored. The use of
viral vectors and stably expressed transgenes will likely pose transla-
tional hurdles due to safety concerns. In addition, the heart contains a
large pool of ﬁbroblasts, necessary for normal function [204]. It may
be detrimental to target all cardiac ﬁbroblasts non-selectively, and
nanoparticulate targeting for ﬁbroblasts present in or near the myocar-
dial scar could aid in avoiding potential off-target effects of non-
selective transdifferentiation. Such nano-particles could be responsive
to stimuli in the scar environment itself, such as inﬂammation or reac-
tive oxygen species, if a sufﬁcient differential in molecular targets is
not present between ﬁbroblasts present in the scar and those elsewhere
in the heart. Similarly, local delivery in biomaterial carriers could help to
produce spatial control and retention of a therapeutic payload at the
border zone.
3.2.4. Growth factors and proteins
Among the different therapeutic agents aimed to regenerate the
damaged heart tissue after an ischaemic disease, peptides and proteins
represent a well-consolidated acellular resource. The increased accessi-
bility to these biopharmaceutical drugs and the advances in chemical
modiﬁcations to enhance protein half-life in vivo and minimize immu-
nogenicity [205] offer a broad range of new therapeutic modalities.
Modiﬁed peptides and proteins can enable cardiac repair through acti-
vation of endogenous cardiac progenitor cells present at the injury
site, the induction of cardiomyocyte proliferation and the recruitment
of progenitor cells to damaged myocardium or of functional cells able
to trigger neovascularisation.
With the aim to replace stem cell therapy in the treatment of acute
myocardium ischaemic injury, Pavo et al. recently suggested the use of
the secretome of apoptotic peripheral blood cells (APOSEC). The para-
crine effects of this mixture of cytokines and growth factors were
assessed after intramyocardial injection in a porcine model of acute
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matory and apoptotic genes 1 month after injection, whereas some
angiogenic factors and regulators of vascular tone and homeostasis
were upregulated. As a consequence, a reduced infarct size and im-
proved hemodynamic function were found in APOSEC-treated animals
[206].
Cell function is controlled by growth factors through the activation
of speciﬁc signalling pathways [207]. The modulation mediated by
these proteins may involve different biological routes and organs in
the body. Therefore, the selection of cardiac-speciﬁc growth factors
and safe dosing regimens should help prevent undesirable off-target
effects. In the case of angiogenesis, vascular endothelial growth factor
(VEGF) has been demonstrated to be a major regulator of vascularisa-
tion under hypoxic conditions. As a potent growth factor for endothelial
cells, VEGF administered after MI can induce angiogenesis and improve
cardiac function. Despite its proven efﬁcacy in preclinical models, VEGF
has failed to achieve successful translation to clinical practice, in part
due to dose limitation derived from the risk of nitric oxide-mediated
hypotension [208]. Additionally, some concerns have been raised
about the progression of metastatic tumour lesions as side effects of
the prolonged administration of angiogenic growth factors.
The chemotactic stromal cell derived factor-I (SDF-I) has been
described as a potent stem cell homing agent that is also involved in
the regeneration of the vasculature. By binding to the CXCR4 receptor,
SDF-I does not act as a growth factor on endothelial cells but increases
the recruitment of endothelial progenitor cells [205]. This fact suggests
a safer mechanism in the induction of angiogenesis since a therapy
based on SDF-I may limit the uncontrolled formation of abnormal ves-
sels. However, a major drawback of using SDF-I lies in its rapid cleavage
by enzymes in the heart, such as DPP-IV andmatrix metalloproteinases,
leading to low efﬁcacy. To surpass this disadvantage and improve its
pharmacokinetics and activity, approaches based on altered SDF-I che-
mokine designs that resist proteases or nanoﬁbre-mediated delivery
of SDF-I have been suggested [209]. In a complementary strategy, the
conjugation of SDF-I to the soluble platelet collagen receptor glycopro-
tein VI, which preferentially binds to collagen at exposed extracellular
matrix in the damaged vasculature, enabled the targeted delivery of
higher concentrations of SDF-I to the infarct site. This approach pro-
duced an enhanced recruitment of functional cells and a signiﬁcant
reduction of the infarct size in mice after MI [210]. Alternatively, gene
transfer has been shown as a safe option in a Phase I clinical trial with
a DNA plasmid encoding human SDF-I, JVS-100. The endomyocardial
injection of the naked plasmid in patients with HF was well tolerated
at all dose levels tested and led to improvements in clinical endpoints
after 4 months [211].
Early clinical studies have also been performed with recombinant
human neuregulin-I (NRG-I), a member of the epidermal growth factor
family that promotes increased cell cycle activity and proliferation of
cardiomyocytes through ErbB4 receptor binding. Patients with stable
chronic HF showed an improved cardiac function with favourable
acute and sustained hemodynamic effects after daily injections of
NRG-I for eleven days [212]. Similarly to NRG-I, periostin can induce
cell cycle reentry in adult cardiomyocytes. Kuhn et al. demonstrated
that differentiated mononucleated cardiomyocytes have proliferative
potential, and that periostin injected into the myocardium of rats after
infarction has a regenerative effect, improving cardiac function after
12 weeks and reducing ﬁbrosis and hypertrophy [213].
Hepatocyte growth factor (HGF) is a mesenchyme-derived pleiotro-
pic factor with a stimulating effect on hepatocyte multiplication. Its im-
plication in the regulation of cell growth,motility andmorphogenesis of
various cell types extends to themodulation of cardiovascular growth in
pathological conditions. The antiapoptotic effect of HGF on cardio-
myocytes has been demonstrated in rats after transient myocardial
ischaemia and reperfusion [214]. Moreover, HGF may inﬂuence angio-
genesis and progenitor cell recruitment. Urbanek et al. showed that a
gradient of HGF facilitated translocation of CSCs from the atrioventriculargroove to the infarcted myocardium in mice [215]. A Phase II
multicentre clinical trial evaluating a small-molecule mimetic of HGF,
BB3, is currently ongoing with the aim to assess the safety of this
drug in conjunction with standard care and its efﬁcacy in improving
heart function in patients following MI [216].
Growth and differentiation of recruited stem cells may be supported
by insulin-like growth factor I (IGF-I). This hormone binds a tyrosine
kinase receptor and enhances cell survival. IGF-I has been shown to
reduce myocardial necrosis and apoptosis, and its overexpression in
transgenic mice leads to an increase inmyocyte turnover thus compen-
sating for the extent of cell death in the ageing heart [217]. Moreover, in
patients who had a diagnosis of ischaemic heart disease, low circulating
IGF-I levels are associated with an increased risk in the development of
cardiovascular disease [218]. The key role of IGF-I in cardiomyocyte
homeostasis suggests a strong therapeutic potential. However, higher
dose regimens have been associated with side effects such as hypoten-
sion and tachycardia. As proposed by O'Sullivan et al., a single local
administration of low-dose IGF-I at 2 h into reperfusion may provide a
prosurvival activity while avoiding signiﬁcant side effects. In a porcine
model of acute MI, the authors showed a reduced cardiomyocyte
death at 24 h after IGF-I injection, which translated into structural and
functional beneﬁts in the regional and global myocardium 2 months
after treatment [219].
In order to increase the bioavailability and control the release of
growth factors in the cardiac tissue, drug delivery systems have been
suggested as a means to protect and accumulate the protein cargo.
Davis et al. reported the use of biotin–streptavidin to bind IGF-I to
self-assembling peptides without interfering with bioactivity. These
peptides provided a sustained IGF-I delivery for more than 1 month in
rat myocardium. However, the co-injection of neonatal cardiomyocytes
was necessary to achieve a therapeutic effect in rats after experimental
MI [220]. To avoid the use of cell therapy, Chang et al. developed a deliv-
ery system based on PLGA nanoparticles functionalized with pPEI,
which was able to electrostatically complex IGF-I. After comparing
growth factor-loaded particles of different sizes (60 nm, 200 nm and
1 μm), the authors found that the 60 nm-sized nanocarriers displayed
the highest IGF-I activity in cultured cardiomyocytes. Following injec-
tion of these particles in the infarcted myocardium of mice, it was
shown that the polymeric carriers prolonged IGF-I retention time and
reduced cardiomyocyte apoptosis by more than 25%. Remarkably, a
single administration of IGF-I-loaded nanoparticles improved cardiac
systolic function, reduced infarct size and prevented ventricular remod-
elling at 3 weeks post-infarction [221].
The feasibility of controlled delivery using polymeric carriers was
also shown for other proteins involved in repair of the damaged heart.
Formiga et al. encapsulated FGF-I and NRG-I separately in PLGA micro-
particles to assess the effect of cytokine sustained release on cardiac
regeneration. The microparticle formulations showed very similar
release kinetics with nearly 70% cumulative release within 1 month.
The injection of the loaded particles into the ischaemic myocardium of
rats produced reductions of the infarct size and ﬁbrosis as well as an in-
crease of the left ventricle thickness 3 months after treatment, with no
signiﬁcant differences among particles loadedwith FGF-I, NRG-I or both
[222]. In a different study with isolated rat cardiomyocytes in vitro,
Johnson and Wang evaluated the protection from degradation and the
sustained release of the morphogen Sonic hedgehog (Shh) from a coac-
ervate delivery system [223]. Shh is known to control the epithelial/
mesenchymal interactions during the embryonic development, and
has demonstrated potential to restore blood ﬂow in a mouse model of
hindlimb ischaemia aftermultiple injections for 1 month [224]. The for-
mulation of Shh-heparin complexes in poly(ethylene argininylaspartate
diglyceride) prolonged the release of Shh for over 3 weeks and pro-
voked an upregulated secretion of VEGF, IGF-I, SDF-I and Shh by cardiac
ﬁbroblasts for at least 2 days.
As an alternative to particle formulations, the encapsulation of pro-
teins in carrier gels also provides a controlled release and enhances
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efﬁcient angiogenesis and collateral ﬂow induced by FGF-2 loaded in
photocrosslinkable chitosan hydrogels. The chitosan aqueous solution
containing FGF-2was applied on the surface of the ischaemicmyocardi-
um and subsequently crosslinked by UV-irradiation for 30 s. Notably,
the chitosan hydrogel allowed an extended delivery of FGF-2 for a peri-
od longer than 1 month [225]. An ideal growth factor carrier should
have the ability to ﬂow through a catheter, enablingminimally invasive
application, and thereafter form a solid gel to avoid the injected drugs to
be pumped out of the heart. In an attempt to develop such a system,Wu
et al. synthesized a biodegradable aliphatic polyester hydrogel, poly(δ-
valerolactone)–poly(ethylene glycol) (PEG)–poly(δ-valerolactone),
which gels when heated at physiological temperature. The injection of
the hydrogel in the infarcted myocardium of rats attenuated adverse
cardiac remodelling and improved ventricular function for up to
35 days. These effects were strengthened by covalently attached
VEGF, which additionally provided increased regional angiogenesis in
comparison with free VEGF co-injected with the hydrogel [226]. With
the same aim to design an injectable biomaterial, Bastings et al.
proposed pH-sensitive ureido-pyrimidinone PEG hydrogels, which are
ﬂuid above pH 8.5 and instantaneously gel at neutral pH. By transcath-
eter injection of the synthetic hydrogel incorporating both HGF and IGF-
I in a porcinemodel of MI, the authors demonstrated a safe administra-
tion and a reduction in scar collagen after 1 month [227].
Tissue regeneration is often characterized by complex cascades of
growth factors with critical roles in cell proliferation and differentiation.
The combination of several growth factors is required to mimic the na-
tive environment and promote the formation of functional tissue [208].
Since myocardial repair involves the contribution of different signalling
pathways, the combined activation by co-administered growth factors
represents a promising approach for an enhanced performance of
CSCs and may also enable effective and safe angiogenic interventions.
Ellison et al. demonstrated the superiority of co-administered HGF
and IGF-I to induce myogenic differentiation of endogenous porcine
CSCs in the presence of adult rat ventricularmyocytes in vitro. The injec-
tion of a small dose of IGF-I and HGF through the coronary artery
supplying the infarcted region in pigs produced a dose-dependent pro-
tective effect on myocardial survival and reduced hypertrophy in the
peri-infarct zone. Furthermore, a reduced infarct size and enhanced
left ventricular functionwere measurable 2 months after the treatment
[228]. In a different approach, Song et al. recently reported the combina-
tion of SDF-I with the angiogenic tetrapeptide Ac-SDKP to activate
regenerative mechanisms in a model of chronic HF in rats. The authors
immobilized Ac-SDKP in acrylated hyaluronic acid hydrogels, in which
SDF-I was added before crosslinking. Interestingly, hydrogels with sin-
gle SDF-I or Ac-SDKP failed to show a signiﬁcant regenerative activity
whereas the dual therapy led to increased angiogenesis, improved left
ventricular function, decreased infarct size and higher wall thickness
at 4 weeks after hydrogel injection [229]. In spite of these promising
preliminary results, more extensive knowledge on the role of different
stem cell homing factors and the potential synergies with differentia-
tion and proliferation mechanisms is needed. As exempliﬁed by some
negative reports on the use of SDF-I therapies for MI in vivo [230], a
tight control of the complex molecular signalling is likely required to
avoid unexpected effects.
Temporal control on the release of proteins is another key factor to
realise their maximal potential for cardiac regeneration. In the case of
granulocyte colony stimulating factor (G-CSF), which induces prolifera-
tion of haematopoietic stem cells with the capacity to regenerate the in-
farcted myocardium, an effect was found only in patients who received
G-CSF early after MI [231]. As hypothesized by Ruvinov et al., a sequen-
tial delivery of IGF-I andHGFmay favour the regenerative process: a fast
release of IGF-I could enhance survival of the remaining functionalmyo-
cardium, while a more sustained release of HGF could induce angiogen-
esis and more favourable remodelling at later stages. By bioconjugating
IGF-I and HGF individually with alginate-sulphate, and combining bothcomplexes with low viscosity sodium alginate solution, dual-release
injectable hydrogels were obtained. The intramyocardial injection of
the alginate gels in a rat model of acute MI produced an increased
cytoprotection and angiogenesis in the infarct after 1 month when
compared to the administration of IGF-I andHGF in saline. Furthermore,
the sequential treatment induced a higher level of cell proliferation at
the infarct border after 1 week, as well as a higher expression of
GATA-4 after 4 weeks, indicative of angiogenesis, survival and stem
cell recruitment [232]. In another example, albumin–alginatemicrocap-
sules were employed to separately incorporate FGF-2 and HGF with
different release kinetics. As the authors of this study suggest, the se-
quential release of FGF-2, which generates a potent angiogenic activity,
followed by the arteriogenic signalling induced by HGF, resulted in a
mature vessel network that prevented cardiac hypertrophy and ﬁbrosis
and led to improved cardiac perfusion after 3 months in a rat model of
chronic HF [233].
Furthermore, a time-controlled combination of immune response
inhibition and neovascularisation was recently achieved by Projahn
et al. By crosslinking thiol-functionalized copolymers of ethylene
oxide and propylene oxide with different agents, i.e. hydrogen peroxide
or PEG-diacrylate, the authors obtained degradable gels with disulphide
or thioether bonds, respectively. In the presence of reduced glutathione,
the disulphide-based gels degraded in 1 day (fast degradable hydrogel,
FDH) while complete degradation of thioethers occurred after 1 month
(slow degradable hydrogel, SDH). On the one hand, an inhibitor of neu-
trophil inﬁltration, MetCCL5, was released from FDH to block the
immune response during the ﬁrst hours. On the other hand, SDF-I was
released from SDH for a sustained recruitment of haematopoietic stem
cells. The co-administration of both loaded hydrogels in the infarcted
myocardium of mice preserved cardiac function, promoted angiogene-
sis and facilitated wound healing processes [234].
Togetherwith ﬁbroblast growth factors, bonemorphogenetic proteins
(BMPs) and wingless-type (Wnt) proteins are involved in the initial
speciﬁcation of cardiac cells. Yoon et al. showed that the combination
of BMP-2 with FGF-4 induced myogenic differentiation of MSCs
in vitro, and that the implantation of MSCs treated with the growth fac-
tors enhanced engraftment and myogenic differentiation in infarcted
myocardium in rats [235]. BMP-2 has been demonstrated to improve
the contractility of individual spontaneously beating cardiomyocytes.
Moreover, intravenous injection of BMP-2 in a mouse model of acute
MI induced a reduction in cardiomyocyte apoptosis up to 4-fold in the
border zone and up to 2-fold in the remote myocardium when com-
pared to negative controls 5 to 7 days after administration [236]. In
the case of Wnt, Duan et al. found that Wnt1 and Wnt7a were signiﬁ-
cantly upregulated after acute cardiac injury. The expression of Wnt1
peaked within 2 days after injury and was sustained at lower levels
for two weeks, driving an early repair response in mice myocardial
ischaemia [237]. It has been demonstrated that theWnt1/β-catenin sig-
nalling system mediates a pro-ﬁbrotic repair in cardiac ﬁbroblasts after
MI. A close correlation of the responsiveness of cardiacﬁbroblast toWnt
and the temporal pattern ofWnt1 expression after heart injury suggests
the role of this pathway during cardiac disease [238].
In addition to its main role in haematopoiesis, erythropoietin (EPO)
presents antiapoptotic and pro-angiogenic properties that have shown
efﬁcacy against MI in different animal models. In rats, intraperitoneal
administration of EPO once every 3 weeks induced new vessel forma-
tion associated with enhanced mobilisation, myocardial homing and
vascular incorporation of endothelial progenitor cells. Accordingly,
VEGF levels increased 4.5-fold in the groups treated with EPO [239].
Kawachi et al. showed that subcutaneous injection of EPO enhanced an-
giogenesis in pigs following MI by upregulating HGF and FGF systemi-
cally and VEGF and IGF in the border and infarct areas [240]. Despite
substantial evidence of EPO effectiveness in vivo, clinical studies failed
to show expected therapeutic efﬁcacy [241]. As suggested by Roubille
et al., meta-analysis of the available data from clinical trials could help
in assessing the impact of factors such as the route of administration
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Fig. 4. The case for advanced delivery, as discussed here, is summarised by fourmain concepts; localised therapy, nanoparticle encapsulation,minimally invasive delivery andmultimodal
approaches.
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of the cardioprotective role of EPO found in animals, larger clinical trials
with consistent inclusion/exclusion criteria might be needed.
Given increasing knowledge on the different molecular pathways in
which growth factors and cytokines are involved and new develop-
ments in biopharmaceutical drug combinations to maximise therapeu-
tic potential, enhanced treatment options for cardiac regeneration are
expected to occur in the coming years. In addition, the formulation of
these therapeutic agents in drug delivery systems will facilitate a safer
administration andmore effective dosing patterns, leading to improved
clinical outcomes.
4. The case for advanced delivery
Regenerative therapy for ischaemic cardiomyopathy is an extremely
active area of research and a variety of potential treatment strategies
have emerged over recent decades. Cell therapy has arguably
progressed furthest towards clinical translation, as evidenced by a
signiﬁcant number of clinical trials, but is still hampered by poor and
unpredictable efﬁcacy when implemented in large patient cohorts.
Indeed, translation of the positive results achievable in preclinical
models has been largely slow and unsatisfactory for all avenues of myo-
cardial regenerative therapy. With this in mind, we elected to review a
selection of therapeutic approaches with a particular focus on advanced
delivery strategies as a method to enhance efﬁcacy, reduce deleterious
effects and aid clinical translation. These concepts are summarised here.1. Localised therapy in biomaterials— this encompasses the local deliv-
ery of therapeutic agents in biomaterial carrier vehicles as opposed to
simple systemic delivery. This is of particular importance for cellular
payloads where a biomaterial can act to mimic the natural ECM, to
enhance survival and provide biological cues for cellular behaviour
and fate. In addition, the localised delivery of small molecules or
growth factors within a biomaterial matrix permits for sustained re-
lease over extended periods to enhance efﬁcacy in target tissues.
2. Nanoparticulate encapsulation — this involves the delivery of thera-
peutics in a nanoparticulate carrier to reduce interaction with off-
target tissues and enhance targeting to the ischaemic myocardium.
3. Multimodal approaches— the concurrent delivery of more than one
therapeutic (for example cells with small molecule drugs) can
achieve synergistic efﬁcacy. Release of therapeutics from either an
implantable biomaterial or nanoparticle system can also be tailored
to mimic a biological cascade. For example, sequential release of
two or more agents can be utilised to target early and late stage efﬁ-
cacy in a physiological process such as angiogenesis [243].4. Minimally invasive delivery approaches — percutaneous catheter
systems can be utilised to locally deliver therapeutic agents to the
heart in a minimally invasive manner, reducing surgical time and
cost, and allowing multiple administrations of therapy.
Theﬁrst two concepts have been addressed in the context of the pre-
vious sections and the following section will focus on the latter points,
discussing the potential of these delivery approaches in the pursuit of
clinical translation and improved treatment outcomes. In particular,
we will discuss the potential for multimodal therapeutics primarily in-
volving the combination of cells with an additional co-delivered thera-
peutic, and the state of the art with regard to minimally invasive
catheter delivery to the myocardium.
4.1. Multimodal therapeutic strategies
A multimodal combination of cells with an additional therapeutic
agent represents a particularly attractive therapeutic strategy. This
approach confers the potential for therapeutic agents to act on co-
delivered cells, as well as exert efﬁcacy in target tissues. Co-delivery in
a biomaterial carrier can ensure that both cells and a second therapeutic
deliverable are kept in close proximity for the duration of therapy to
enhance synergistic interaction (Fig. 4).
A number of studies have addressed the potential of co-delivering
cells with growth factors to produce therapeutic angiogenesis, which
could be of signiﬁcant utility in the treatment of ischaemic cardiomyop-
athy. The hindlimb ischaemiamodel is often used to gauge the potential
of a given therapeutic strategy to produce vascular growth. For example,
Saif et al. administered PLGA microparticles containing a triple combi-
nation of VEGF, HGF and Angiopoietin-1 (Ang-1) alone, human cord
blood vasculogenic progenitor cells (ECFCs) alone, or a combination of
both, via intramuscular injection in a murine hindlimb ischaemia
model. Cells or growth factor loaded particles alone produced a modest
increase in vascularisation and limb perfusion but a multimodal combi-
nation produced a substantial further increase. The biomimetic ratio-
nale was to combine two potent pro-angiogenic agents, VEGF and
HGF, with a vessel pro-maturation agent, Ang-1. This was proposed to
avoid the phenomenon of leaky and poorly functional vessels which
can in some cases occur upon treatment with VEGF alone. In an ear tis-
sue leakage assay, the authors showed that administration of VEGF
alone produced signiﬁcantly leaky vessels, which was somewhat ame-
liorated by co-administration of HGF and signiﬁcantly reduced by triple
administration of VEGF, HGF and Ang-1. The triple combination also
produced more vessels than VEGF/HGF co-administration, highlighting
the importance ofmultimodal administration and biomimetic strategies
to enhance efﬁcacy [244].
Table 2
Comparison of commercially available cell injection catheters by access, core needle outer
diameter, material and shape.
Device Manufacturer/research group Needle shape
Endocardial delivery
Helix BioCardia Helical
MyoCath Bioheart Straight, can be deﬂected
MyoCath II Bioheart Weeping
C-Cath® Cardio3 Biosciences Curved, large-to-small side
holes
Myostar Bioheart Straight
Stiletto Straight
Transvascular
TransAccess Medtronic Curved
Cricket/Bull-Frog Mercator Medical Straight, mounted on
balloon
Epicardial
Cell-Fix Chachques group Straight, attached to
“sucker” ﬁxation system
Intracoronary perfusion
PTCA devices Multiple No needle, cells delivered
through guidewire lumen
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investigated in the infarcted myocardium. Dvir et al. investigated the
delivery of neonatal rat cardiac cells on an alginate patch containing
bound IGF-1, SDF-1 and VEGF to act as a co-delivered pro-survival and
pro-angiogenic cocktail. The patch was prevascularised on the omen-
tum before implantation on the infarcted rat heart. Patches containing
growth factors demonstrated enhanced vascularisation on the omen-
tum, and prevascularised patches produced greater myocardial regen-
eration in terms of increase in left ventricular function and reduction
in ventricular remodelling, although patches containing no growth fac-
tors were not investigated in the infarcted heart [245].
Padin-Iruegas et al. injected self-assembling peptide nanoﬁbreswith
tethered IGF-1 (NF-IGF-1) alone, rat CPCs (rCPCs) or a combination of
both in a rat myocardial infarct model, with the rationale that co-
delivered IGF-1 would increase delivered cell survival along with
enhancing the regenerative response of resident CPCs. Both CPCs and
NF-IGF-1 were injected intramyocardially and NF-IGF-1 facilitated pre-
sentation of bioactive IGF-1 for a sustained period. Combination therapy
produced greater enhancement in LVEF, increased the presence of
newly formed cardiomyocytes (230% compared to NF-IGF-1 alone),Epicardial
Delivery
Transvascular 
Delivery
Fig. 5. Current access routes for cell-based therapies to the heart include transvascular deliver
device designed for each delivery route is depicted in this ﬁgure.and increased infarct vascularisation and reduction in infarct size, with
respect to the delivery of cells or IGF-1 nanoﬁbres alone. In addition,
combination therapy enhanced the activation of resident CPCs [246].
Takehara et al. administered bFGF in a gelatin hydrogel sheet alone,
human cardiosphere derived cells (hCDCs) alone, or a multimodal
combination of both to the infarcted porcine myocardium via
intramyocardial injection (hCDCs) or surgical implantation on the epi-
cardium (hydrogel sheet). Sustained release of bFGF from the gelatin
sheet for up to three weeks was achieved. Delivery of bFGF/gelatin
alone enhanced myocardial perfusion and LVEF while hCDCs alone en-
hanced LVEF and reduced infarct volume. Co-delivery of hCDCs and
bFGF/gelatin signiﬁcantly enhanced hCDC engraftment in the myocar-
dium and resulted in synergistic increases in LVEF and reductions in in-
farct size, compared with delivery of either hCDCs or bGF/gelatin alone.
No synergistic effects were observedwhen bone-marrow-derived hMSCs
were co-delivered with bFGF, supporting the hypothesis that cardiac-
derived stem cells are likely more suited for cardioregenerative applica-
tions [247].
On the basis of these promising results this approach (CSC/bFGF
therapy) has progressed to a small Phase I clinical trial, ALCADIA (AutoL-
ogous human CArdiac-Derived stem cell to treat Ischemic cArdiomyop-
athy) to determine the safety of the approach. Autologous CSCs were
administered to patients via intramyocardial injection and bFGF/gelatin
sheets were implanted epicardially, during bypass surgery. Patients
demonstrated increased LVEF and reduced infarct size after the surgical
procedure, but in the absence of a control group and as a result of a small
patient cohort, deﬁnitive conclusions about efﬁcacy were not possible.
The trial demonstrated that the approach was safe and feasible and fur-
ther trials will establish the efﬁcacious potential of this approach [248].
In an interesting acellular hybrid therapy approach Kubota et al.
employed an atelocollagen sheet/polyglycolic acid ventricular restraint
device (VRD) alone, a small molecule PGI2 agonist ONO1301 on an
atelocollagen sheet alone, or a multimodal ONO1301-doped VRD in a
canine model of myocardial infarction. At 8-weeks post-infarction
hearts treated with the multimodal VRD demonstrated the greatest
increase in LVEF, greatest reduction in left ventricular wall stress and
ventricular remodelling. All hearts treated with ONO1301 (either
alone or in combination with VRD) demonstrated an increase in myo-
cardial vascularisation and upregulation of HGF, VEGF and SDF-1 in
the myocardium [249]. In a similar hybrid approach with cells, Shafy
et al. showed that the combination of adipose-derived stem cells
(injected into the infarct and seeded in a collagen matrix) with a poly-
ester CorCap VRD device resulted in signiﬁcant improvements inIntracoronary 
Perfusion
Endocardial Delivery
y, intracoronary perfusion, epicardial delivery and endocardial delivery. An example of a
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infarct model [250]. This semi-degradable ventricular bioprosthesis ap-
proach is an example of biomaterial-mediated cell therapy combined
with a constraint device. The CELLWAVE study addressed delivery of
BM-MSCs combined with a pretreatment of low energy cardiac shock-
wave to improve honing of cells and expression of SDF-1 and VEGF.
The combination of shock wave with cells resulted in an increase in
ejection fraction of 3.2% [251]. Chachques has bioengineered nano-
biomaterials with elastomeric membranes to create a controlled drug
release patch, which they can tailor for local cell attraction and cell
differentiation [252].
Multimodal approaches show particular promise for myocardial re-
generation. However, the biomedical industry is sometimes reluctant to
pursue such therapeutic strategies due to the concern that it could result
in a longer regulatory process and consequent delays in bringing a prod-
uct to market. Multimodal therapeutics can be more difﬁcult to classify
and categorise since they involve a variety of therapeutic elements.
However, the enhanced potential for improved treatment outcomes
and therefore a product with a greater chance of obtaining clinical
approval means that multimodal approaches should receive serious
consideration for future therapies. This is especially true given the lack
of concrete clinical translation in this ﬁeld to date, despite decades of
research, primarily into simplistic treatment approaches involving sys-
temic delivery of single agents or cells. The FDA opened an Ofﬁce of
Combination Products in 2002, speciﬁcally to provide guidance to clarify
the regulation of combination therapies and to enable timely and effec-
tive premarket review of combination products [253]. In addition, pre-
clinical and clinical safety and efﬁcacy data for pre-existing single
agent regenerative therapeutics are likely relevant to new combination
product applications, reducing the overall regulatory burden.
4.2. Minimally invasive therapy — catheter delivery
It is important that deliverable therapeutic formulations reach the
region of the infarcted myocardium where they are most required. The
heart resides in the thoracic cavity and in general is accessed via highly
invasive surgical procedures involving a thoracotomy, contributing to
signiﬁcant costs and patient morbidity. In order to facilitate localised
delivery to the myocardium in a minimally invasive way, percutaneous
catheter delivery can be employed. Percutaneous catheters are medical
deviceswhich generally consist of ﬂexible, hollow tubing and an associat-
ed guide wire with a distal ‘active’ tip which performs an injection. The
device can be passed into the vasculature through a small incision,
advanced and manipulated via a proximal handle, until the tip reaches
the therapeutic target.
Catheter delivery of cells alone, typically in a saline carrier, has been
more explored than catheter delivery of more advanced materials such
as patches or hydrogels, and will be discussed brieﬂy here. The trans-
catheter cardiac cell delivery ﬁeld has recently been directed at improv-
ing cell retention. In contrast to thoracic surgical injections or patch
implantations, transcatheter approaches are less invasive. They allow
the effect of cell therapy to be evaluated independently of other surgical
procedures, and justify multiple deliveries of cells. The following
sections will describe existing delivery systems, their capabilities, and
will suggest potential for innovation in areas where suitable devices
are not commercially available. For a more detailed insight into current
systems the reader is referred to two review papers on this area [254,
255]. Several catheter-based access approaches have been used in
humans; directly injecting cells into the ventricular wall (epicardial,
endocardial and transvascular approaches), and infusing cells into the
coronary arteries using existing balloon angioplasty catheters [254,
255]. Table 2 and Fig. 5 describe a panel of available devices. The deliv-
ery systemsdiffer in their access approach, but share some common fea-
tures; a low proﬁle core element dedicated to transport cells, which has
a bevelled needle to anchor into the myocardium, and outer compo-
nents to protect the core and deliver it to the infarcted tissue.The endocardial delivery devices approach the myocardium from
inside the ventricle. As for many interventional cardiology catheteriza-
tions, they are introduced to the arterial system transfemorally or
transradially, guided around the aorta, and through the aortic valve in
a retrograde fashion. Catheters are manipulated inside the ventricle by
support catheters or steerable designs, and can rely heavily on imaging
systems for accurately targeting injection sites at ischaemic areas or the
infarct border zone. Transvascular devices approach the myocardium
from the epicardial surface. A support catheter is placed through the
femoral veins, and tracked around to one of the coronary veins. By
using an IVUS (IntraVascular UltraSound) system, the nearby coronary
artery and the pericardium can be localised. The coronary vein is then
punctured with a small needle, and the injection catheter is passed
through this puncture site to the epicardial wall. For epicardial access,
the Cell-Fix catheter includes a retractable needle and a polyurethane
umbrella shaped suction systemwhich ﬁxes the device to the epicardi-
um when connected to vacuum. This allows stability for penetration
and retraction of the injection needle [256]. The goal of intracoronary
infusion is to increase the number of cells delivered to the ischaemic
myocardium. Vessels are visible by angiography techniques and if cells
are injected proximally, they can be distributed to large areas of the
myocardium. The method uses established interventional cardiology
tools such as Percutaneous Transluminal Coronary Angioplasty (PTCA)
devices, where the cells are delivered through the guidewire lumen on
removal of the guidewire when the device has been steered through
the vasculature to the culprit vessel. Limitations include the fact that
large cells in viscous suspensions may not be appropriate due to the
risk of obstruction, and cells used must be capable of migrating across
the endothelium to perivascular spaces. Furthermore, if patients have
chronic total occlusion, this approach is not feasible. PTCA catheters
are not designed or approved for cell infusion, and there are no standard
tests to compare them for this purpose. Early studies with these devices
reported low retention of cells from direct injection, retrograde venous
delivery and intracoronary perfusion groups, albeit with slightly higher
numbers for the direct injection group [68,257]. More recently, analyti-
cal and numerical modelling based on the Darcy Law and transport
mass retention has led to optimised needle designs speciﬁcally for cell
retention [258]. The use of a small-to-large graded side-hole design in
a 75° curved Nitinol needle in the C-Cath lessened interstitial pressure
during delivery to improve retention and resulted in a signiﬁcant (N3-
fold) increase in cell retention (healthy and infarcted hearts) [258].
While the catheters described here are a huge improvement on simple
systemic or invasive local delivery, they are limited in that they are
only optimised to deliver a simple saline payload which doesn't facili-
tate sustained release or cell viability; there is still a need for catheters
delivering retentive materials such as injectable hydrogels or epicardial
patches.
4.2.1. Catheters for material based approaches
Existing catheter technology may not be appropriate for injecting
hydrogels due to considerations such as rapid gelation kinetics, hydro-
gel viscosity and complications with gelation triggers such as thermal
sensitivity or requirements for mixing and incorporation of crosslinking
agents immediately prior to injection. Additionally, there is a lack of
available devices for catheter-based delivery of preformed scaffolds,
patches or cell sheets. For injectable hydrogels, certain catheter design
criteria need to be fulﬁlled to maintain the liquid prepolymer during
catheter transit to the injection site, to allow fast gelation in situ once
the polymer has been injected, and to provide multiple deliveries with-
out issues such as needle blockage. New cyto-compatible catheterized
devices such as double-barrel injectors (to mix chemically crosslinked
gel precursors with crosslinking agents), cooled catheters (for thermo-
responsive gel payloads) and epicardial patch deployment tools are
needed. Several preclinical studies have determined the feasibility of
delivering injectable hydrogels to the heart using commercially avail-
able catheter systems. For example, Leor et al. delivered an alginate
100 C.L. Hastings et al. / Advanced Drug Delivery Reviews 84 (2015) 85–106hydrogel to the coronary vessels in pigs using an injection catheter
[149]. Martens et al. determined the optimumviscosity and gelation pa-
rameters for a ﬁbrin hydrogel for use with a range of commercially
available catheters [109]. Singelyn and Christman determined that an
in-situ gelling decellularised myocardial matrix was compatible with
catheter delivery [91]. Other groups have improved conventional cath-
eters or syringes for their purposes; Koﬁdis et al. describe a Y-shaped
applicator for two syringeswhere thematrix is contained in one syringe
and cell suspension in the other whereby homogeneous mixing occurs
on injection [154].
Until now, delivery of patches or scaffolds in preclinical trials has
been performed in a surgically invasive manner during open chest pro-
cedures. Patches are still largely delivered to the epicardium, due to con-
cerns of embolization upon endocardial deployment. The ﬁeld of
epicardial delivery could learn lessons from other interventional ﬁelds,
such as that of Total Aortic Valve Replacements (TAVIs) and other pro-
cedures using the transapical delivery approach. This access route
could be a promising candidate for epicardial material mediated-
delivery. In this approach, access to the epicardium is undertaken via a
mini-thoracotomy and a pericardial incision. Device proﬁle is only
limited by the constraints of the pericardial space, therefore design con-
straints of transapical access catheters are not as limiting as transvascular
catheters when delivering a material that requires a higher proﬁle cathe-
ter bore. These tangible design targets and the signiﬁcant amount of
research in the evolving ﬁeld of material based therapy are compelling
reasons for innovation inminimally invasive delivery systems for materi-
al-based cardiac regenerative therapy. Finally, ventricular restraint
devices can be combinedwith cells, biomaterials or endogenous targeting
approaches. Clinical trials have investigated the delivery of cells while
patients are receiving left ventricular assist devices (for example the
ASSURANCE trial NCT00869024), and the hybrid approach of ventricular
unloadingwith cell delivery has shownpromise for improving native car-
diac function, allowing removal of mechanical assistance and potentially
obviating the need for a heart transplant [259–262]. Future promising
work will focus on combining cells with extra-cardiac assist devices for
biomaterial-based cell delivery on assist device implantation with multi-
ple follow-ups, consisting of minimally invasive cell administrations (a
cell ‘top-up’ dose) via transvascular catheter delivery. Local delivery of
biomaterials via catheter systems could reduce the time, invasiveness
and cost of a given therapeutic procedure while capitalising on the pro-
retentive, cytocompatible and sustained release properties of biomaterial
therapeutic formulations. Future development of such systems might
greatly aid clinical translation of cardiac regenerative strategies.
4.3. Conclusion
Advanced delivery strategies are of the utmost importance in fully
realising regenerative therapies for the treatment of ischemic cardiomy-
opathy. Simple delivery of cells, growth factors or drugs has shown
promise, especially pre-clinically. However, clinical translation remains
elusive. Physiological and pathological processes in the heart are inher-
ently complex, and consequentlymore sophisticated therapeutic strate-
gies which fully utilise advanced delivery techniquesmay be required to
enable clinical translation. The preclinical evidence presented in this
review suggests that an ideal therapeutic might utilise a combination
of the discussed delivery approaches. This strategy might involve mini-
mally invasive catheter delivery of a biomaterial carrier vehicle. The
implanted biomaterial bolus should ideally contain a multimodal pay-
load consisting of cardiac-derived stem or progenitor cells combined
with biomaterial-encapsulated nanoparticles. Suchnanoparticles should
facilitate a controlled release of bioactive molecules which exert thera-
peutic efﬁcacy on co-encapsulated cells and local tissue for sustained
periods. Alternatively, bioactive molecules could be free-loaded into
the biomaterial matrix, provided a sustained release is possible. The for-
mulation should seek to maximise myocardial retention and uptake.
Where possible, the formulation should seek to emulate endogenousbiological cues and processes to maximise efﬁcacy, through judicious
alteration of design criteria such as duration and sequence of bioactive
molecule release, spatial presentation of implanted therapeutics and
manipulation of encapsulated cell behaviour and fate. If systemic deliv-
ery is required, it should be undertaken using targeted nanoparticles to
enhance drug accumulation in myocardial tissue and reduce off target
effects.
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